The advent of multiple third‐gen EGFR TKIs has dramatically transformed the treatment landscape for NSCLC while simultaneously complicating decision‐making for both patients and clinicians [19, 20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.